Global knowledge › Archives › Vol. 9 No. 2 (2024): GLOBAL KNOWLEDGE JOURNAL › Article

C peptide in diagnosis and differentiation of type I and type II diabetes

Joselyn Nicole Culqui Chávez
Universidad Técnica de Ambato
ORCID https://orcid.org/0000-0002-7344-3553
Álvaro Sebastián Ron Mora
Universidad Técnica de Ambato
ORCID https://orcid.org/0000-0003-1157-1661
Abstract

Diabetes mellitus is a chronic metabolic condition characterized by elevated blood glucose levels due to a deficiency in insulin production or action. In this context, C-peptide is a valuable biomarker to evaluate the function of pancreatic beta cells, which play a crucial role in the pathophysiology of diabetes mellitus. The objective is to analyze the role of C peptide in the diagnosis and differentiation between type I and type II diabetes, in order to evaluate its clinical usefulness and its potential impact on medical practice. An exhaustive investigation was carried out in different databases to identify studies related to the topic of interest. The studies reviewed indicated that C-peptide's ability to reflect beta cell function more accurately than insulin alone makes it especially attractive as a diagnostic and differentiation tool. It was concluded that C-peptide has promising potential as a biomarker. in the diagnosis and differentiation between type I and type II diabetes. However, more studies are required to validate its accuracy and clinical utility in different populations and clinical contexts.

How to Cite
Culqui Chávez, J. N., & Ron Mora, Álvaro S. (2024). C peptide in diagnosis and differentiation of type I and type II diabetes. Global Knowledge, 9(2), 349-356. https://doi.org/10.70165/cglobal.v9i2.427
References

Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Diabetes tipo 1. The Lancet, 69–82. https://smiba.org.ar/curso_medico_especialista/lecturas_2022/Diabetes%20tipo%201.pdf

Blanco Naranjo, E. G., Chavarría Campos, G. F., & Garita Fallas, Y. M. (2021). Estilo de vida saludable en diabetes mellitus tipo 2. Revista Medica Sinergia, 6(2), e639. https://doi.org/10.31434/rms.v6i2.639

Chila García, K. C., & García Merlin, L. P. (2023). Niveles de péptido C y hemoglobina glicosilada según el tipo de tratamiento en pacientes diabéticos tipo II del IESS – esmeraldas. Ciencia Latina Revista Científica Multidisciplinar, 6(6), 13848–13869. https://doi.org/10.37811/cl_rcm.v6i6.4374

Cisneros, M. A. (2013). “DETERMINACIÓN DEL PÉPTIDO C COMO INDICADOR DE RESERVA PANCREÁTICA EN RELACIÒN CON LA GLUCOSA EN LOS PACIENTES DIABÉTICOS TIPO 2 QUE ACUDEN AL HOSPITAL UNIVERSITARIO DE MOTUPE". [Universidad Nacional de Loja]. https://dspace.unl.edu.ec/jspui/bitstream/123456789/20052/1/tesis%20Maria%20Augusta%20Cisneros-ilovepdf-compressed.pdf

Conget, I. (2002). Diagnóstico, clasificación y patogenia de la diabetes mellitus. Revista Española de Cardiología, 55(5), 528–538. http://www.revespcardiol.org/es-diagnostico-clasificacion-patogenia-diabetesmellitus-articulo-13031154

Davis, A. K., DuBose, S. N., Haller, M. J., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Goland, R. S., Greenberg, E. M., Liljenquist, D. R., Ahmann, A. J., Marcovina, S. M., Peters, A. L., Beck, R. W., & Greenbaum, C. J. (2015). Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. Diabetes Care, 38(3), 476–481. https://doi.org/10.2337/dc14-1952

Ghorbani, A. (2015). Pathological consequences of C-peptide deficiency in insulin-dependent diabetes mellitus. World Journal of Diabetes, 6(1), 145. https://doi.org/10.4239/wjd.v6.i1.145

González, J. (2019, January 29). PRUEBAS DIAGNÓSTICAS (I): SENSIBILIDAD Y ESPECIFICIDAD. Madri+d Blogs. https://www.madrimasd.org/blogs/fisioterapia/2019/01/29/sensibilidad-y-especifidad/

Gonzalo González, R. (2015). ANÁLISIS DE LOS FACTORES QUE PREDICEN LA REMISIÓN DE LA DIABETES MELLITUS TIPO 2 EN PACIENTES OBESOS MÓRBIDOS TRAS BYPASS GÁSTRICO EN Y-DE-ROUX.

Iqbal, S., Jayyab, A. A., Alrashdi, A. M., & Reverté-Villarroya, S. (2023). The Predictive Ability of C-Peptide in Distinguishing Type 1 Diabetes From Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrine Practice, 29(5), 379–387. https://doi.org/10.1016/j.eprac.2023.01.004

Jones, A. G., & Hattersley, A. T. (2013). The clinical utility of C‐peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30(7), 803–817. https://doi.org/10.1111/dme.12159

Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017). A Practical Review of C-Peptide Testing in Diabetes. Diabetes Therapy, 8(3), 475–487. https://doi.org/10.1007/s13300-017-0265-4

Levitt Katz, L. E., Jawad, A. F., Ganesh, J., Abraham, M., Murphy, K., & Lipman, T. H. (2007). Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatric Diabetes, 8(2), 53–59. https://doi.org/10.1111/j.1399-5448.2007.00236.x

López-Tinoco, C., Vergara-Chozas, J., & Aguilar-Diosdado, M. (2006). Parámetros analíticos en el paciente con diabetes mellitus. Endocrinología y Nutrición, 53(6), 418–426. https://doi.org/10.1016/S1575-0922(06)71124-X

Lozano, J. A. (2006). Diabetes Mellitus. Offarm, 25(10), 66–78. http://www.elsevier.es/es-revista-offarm-4-articulo-diabetes-mellitus-13095504

Maddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022). C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. In Diabetes, Obesity and Metabolism (Vol. 24, Issue 10, pp. 1912–1926). John Wiley and Sons Inc. https://doi.org/10.1111/dom.14785

Maheshwari, A. (2023). Insights on C-peptide in diabetes. IP Journal of Nutrition, Metabolism and Health Science, 6(2), 63–65. https://doi.org/10.18231/j.ijnmhs.2023.009

Marselli, L., Suleiman, M., Syed, F., Filipponi, F., Boggi, U., Marchetti, P., & Bugliani, M. (2015). The β-Cell in Human Type 2 Diabetes. In Islets of Langerhans (pp. 801–815). Springer Netherlands. https://doi.org/10.1007/978-94-007-6686-0_16

Muzzio, M., & Meroño, T. (2020). Características y utilidad clínica de la medida de péptido C. Bioquímica y Patología Clínica, 84(1).

Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., & Steffes, M. W. (2004). C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function. Diabetes, 53(1), 250–264. https://doi.org/10.2337/diabetes.53.1.250

Ramos-Leví, A. M., Matía, P., Cabrerizo, L., Barabash, A., Torrejón, M. J., Sánchez-Pernaute, A., Torres, A. J., & Rubio, M. A. (2013). El péptido C predice la remisión de la diabetes mellitus tipo 2 tras cirugía bariátrica. Nutricion Hospitalaria, 28(5), 1599–1603. https://doi.org/10.3305/nh.2013.28.5.6554

Shields, B. M., Peters, J. L., Cooper, C., Lowe, J., Knight, B. A., Powell, R. J., Jones, A., Hyde, C. J., & Hattersley, A. T. (2015). Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. In BMJ Open (Vol. 5, Issue 11). BMJ Publishing Group. https://doi.org/10.1136/bmjopen-2015-009088

THE NATIONAL ACADEMY OF CLINICAL BIOCHEMISTRY. (2011). Guías y recomendaciones para el diagnóstico y manejo de la diabetes mellitus. 726–728. http://www.scielo.org.ar/pdf/abcl/v46n4/v46n4a15.pdf

Wajchenberg, B. L. (2007). β-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endocrine Reviews, 28(2), 187–218. https://doi.org/10.1210/10.1210/er.2006-0038

Wysham, C., & Shubrook, J. (2020). Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. Postgraduate Medicine, 132(8), 676–686. https://doi.org/10.1080/00325481.2020.1771047

Yin, P., Shao, P., Liu, H., Li, W., Wang, L., Wang, J., Zhang, S., Leng, J., Li, N., Tian, H., Yang, X., Yu, Z., & Hu, G. (2017). C-peptide levels and the risk of diabetes and pre-diabetes among Chinese women with gestational diabetes. Journal of Diabetes and Its Complications, 31(12), 1658–1662. https://doi.org/10.1016/j.jdiacomp.2017.08.006

Downloads

Download data is not yet available.